Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.

Hussein G Elsayed; Moayyad Jalal; Anas Almarrakshi; Ahlam Almasaari; Amal Alabulwahab; Fatimah Alhawsawi; Amjad Alharbi; Asmaa Almaddani; Ahmed Zeineldeen

doi:10.24911/IJMDC.51-1611143630

2024, Vol: 8, Issue: 4

8 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

« Previous Article

Original Article

Online Publishing Date:
21 / 01 / 2021

IJMDC. 2021; 5(2):

doi: 10.24911/IJMDC.51-1611143630

Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.

Hussein G Elsayed, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, Ahmed Zeineldeen.

Abstract
Background: Tyrosine kinase inhibitors revolutionized the treatment of chronic myeloid leukemia. The present study aimed to review the efficacy and tolerance of Imatinib in a group of patients who are treated outside the clinical trial.
Methodology: CML patients presenting to King Abdulla Medical (KAMC), Mecca, Saudi Arabia, during the period between June 2010 and December 2019 were included in this study. All started Imatinib as the first line. Evaluation of response was done according to ELN 2020 recommendation.
Results: 141 patients were included in this study with a male to female ratio of 1.1 and a median age of 42. The majority of patients were considered to be at low risk (70.2%) as by EUTOS risk score. For the whole group, the median follow up was 47.7 months. At 36 m, the OS was 94.8%, which continued as there was no death afterward. Mean event-free survival was 65 m (95% CI 55.6-72.5) with a median of 56.5m. It was significantly longer in those with a low-risk score (p = 0.0001), patients with favorable molecular responses at 3,6,12 m, and compliant patients. Favorable molecular responses were obtained in 67%,53%,51% at 3,6,12 months respectively. Factors that affected molecular responses were higher Hemoglobin, higher platelets, lower blasts, basophils, low-risk score, and better compliance.
Conclusion: In a real-life setting, the efficacy of Imatinib in CML patients was found high coupled with a safe toxicity profile.

Key words: CML, Imatinib, Saudi Arabia, real world.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Hussein G Elsayed Articles by Moayyad Jalal Articles by Anas Almarrakshi Articles by Ahlam Almasaari Articles by Amal Alabulwahab Articles by Fatimah Alhawsawi Articles by Amjad Alharbi Articles by Asmaa Almaddani Articles by Ahmed Zeineldeen
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC. Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Web Style

Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. https://www.ijmdc.com/?mno=47229 [Access: March 27, 2024]. doi:10.24911/IJMDC.51-1611143630

AMA (American Medical Association) Style

Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC. Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Vancouver/ICMJE Style

Elsayed HG, Jalal M, Almarrakshi A, Almasaari A, Alabulwahab A, Alhawsawi F, Alharbi A, Almaddani A, Zeineldeen A. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC, [cited March 27, 2024]; Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Harvard Style

Elsayed, H. G., Jalal, . M., Almarrakshi, . A., Almasaari, . A., Alabulwahab, . A., Alhawsawi, . F., Alharbi, . A., Almaddani, . A. & Zeineldeen, . A. (2021) Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. IJMDC, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Turabian Style

Elsayed, Hussein G, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, and Ahmed Zeineldeen. 2021. Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. International Journal of Medicine in Developing Countries, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Chicago Style

Elsayed, Hussein G, Moayyad Jalal, Anas Almarrakshi, Ahlam Almasaari, Amal Alabulwahab, Fatimah Alhawsawi, Amjad Alharbi, Asmaa Almaddani, and Ahmed Zeineldeen. "Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.." International Journal of Medicine in Developing Countries Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Elsayed, H. G., Jalal, . M., Almarrakshi, . A., Almasaari, . A., Alabulwahab, . A., Alhawsawi, . F., Alharbi, . A., Almaddani, . A. & Zeineldeen, . A. (2021) Real life experience using Imatinib as first line treatment in chronic myeloid leukemia; single Saudi institution study.. International Journal of Medicine in Developing Countries, Online First: 21 Jan, 2021. doi:10.24911/IJMDC.51-1611143630

Most Viewed Articles

Most Accessed Articles

Marginal adaptation of fixed prosthodontics
Shahad Mohammed Halawani, Sahar Amer Al-Harbi
IJMDC. 2017; 1(2): 78-84
» Abstract » doi: 10.24911/IJMDC.1.2.7

Parasites in central nervous system
Amal Ahmed Mohamed, Asmaa Mohamed Mansour
IJMDC. 2017; 1(2): 72-77
» Abstract » doi: 10.24911/IJMDC.1.2.6

Non-diabetic retinopathy: a case report
Hassan F. Alkwikbi, Nabil Mamon Abdelfattah, Haithem Mamon Abdelfattah
IJMDC. 2017; 1(1): 33-37
» Abstract » doi: 10.24911/IJMDC.1.1.6

Vitamin D deficiency among high school female students in Riyadh
Sahar Mohsen Aldhafeeri, Fatemah Ibraheem Alrawaji, Abrar Mubarak Algharbi, Alanoud Abdullah Alhessan, Ayat Sami Qabaja, Ghaleah Abdulaziz Alnassar, Ghaliah Ofayn Alsulami, Mashael Belal Alrubaian, Norah Abdulaziz Alhatim, Salehah Salih Alotaibi, Zahra Ali Alkhamees
IJMDC. 2017; 1(1): 18-23
» Abstract » doi: 10.24911/IJMDC.1.1.4

Prognosis of chronic complications of diabetes mellitus (DM) after multiple events of diabetic ketoacidosis (DKA)
Baraa Faiez Rajab, Anwar Essa Alamrim, Ali Essa Alamri
IJMDC. 2019; 3(5): 474-479
» Abstract » doi: 10.24911/IJMDC.51-1546551993

Most Downloaded

Top Downloaded Articles

Anti-IL-17 markedly inhibited the in vitro granuloma induced by Schistosoma mansoni soluble egg antigen.
Asmaa Ezz, Irene S. Gmail, Fatma Elzahraa H. Salem, Rabab Salama, Soad Nady
IJMDC. 2018; 2(January 2018): 38-46
» Abstract » doi: 10.24911/IJMDC.2.1.7

Antibiotic Resistance Crisis
Nuha Saad Mobarki, Buthaina Abdullah Almerabi, Ahmad Hattan Hattan
IJMDC. 2019; 3(6): 561-564
» Abstract » doi: 10.24911/IJMDC.51-1549060699

The knowledge of mothers about children malnutrition and associated factors
Anas Abdulrahman Aljohani, Mujahid Abdulrahman Aljohani
IJMDC. 2020; 4(1): 7-11
» Abstract » doi: 10.24911/IJMDC.51-1541620358

Knowledge and attitude of caregivers of cerebral palsy children in Riyadh city
Abdulaziz Alruwaished, Baleegh Ali, Lubna Abdullah Alhowaimil , Abaraa adullah Alhowaimil, Najd Abdullah Alhowaimil, Aminah Alessa
IJMDC. 2020; 4(1): 12-17
» Abstract » doi: 10.24911/IJMDC.51-1547833051

Most Cited Articles

Most Cited Articles

Antibiotic Resistance Crisis
Nuha Saad Mobarki, Buthaina Abdullah Almerabi, Ahmad Hattan Hattan
IJMDC. 2019; 3(6): 561-564
» Abstract » doi: 10.24911/IJMDC.51-1549060699
Cited : 34 times [Click to see citing articles]

Prevalence of depression, anxiety and stress among diabetes mellitus patients in Arar, Northern Saudi Arabia
AMohammed Elamin Mukrim, Nujud Muteb D. Alshammari, Wurud Muteb D. Alshammari, Maali Subhi T. Alshammari, Yousef Nasif R. Alshammari, Abdulaziz Sael M. Alshammari, Maisa Hamad F. Alanazi, Abdulelah Abdulrhman F. Alzammam, Muharib Mana M. Alshammari, Slwa Khaled Abu Asyah, Aseel Jamal Alzuhayri, Mushref Saeid Alshammari
IJMDC. 2019; 3(3): 229-233
» Abstract » doi: 10.24911/IJMDC.51-1542576396
Cited : 8 times [Click to see citing articles]

Knowledge, attitude, and practice of breast self-examination toward breast cancer among female students at King Saud University in Riyadh, Saudi Arabia
Abdullah Nasser Alomair, Dania Ghazi Felemban, Mohannad Sami Felemban, Jameel Abdullah Awadain, Ammar Saud Altowairqi, Nawaf Fawzan Alfawzan, Fatimah Mohammed Almazayen, Abdulrahman Jalwi Korkoman, Nawaf Saad Alrusayyis
IJMDC. 2020; 4(2): 429-434
» Abstract » doi: 10.24911/IJMDC.51-1576668182
Cited : 8 times [Click to see citing articles]

Population awareness about rheumatoid arthritis in Jazan region, Saudi Arabia
Ahmad Ali Hazzazi, Mohssen Hassen Ageeli, Ahmed Ali Muyidi, Abdulaziz Mohammad Abulgasim, Abdullah Ahmad Yateemi, Nabil Alhakami
IJMDC. 2020; 4(3): 668-675
» Abstract » doi: 10.24911/IJMDC.51-1576010943
Cited : 4 times [Click to see citing articles]

Prevalence and factors associated with depression among health care workers in National Guard Hospital in Riyadh, KSA
Noor Mohammad AlFahhad
IJMDC. 2018; 2(September 2018): 92-96
» Abstract » doi: 10.24911/IJMDC.51-1526306040
Cited : 4 times [Click to see citing articles]

About International Journal of Medicine in Developing Countries

Contact Information

How to cite this article